Amanote Research
Register
Sign In
Trial of an Oral Hypoglycaemic Agent in Diabetes
BMJ
doi 10.1136/bmj.2.4990.440
Full Text
Open PDF
Abstract
Available in
full text
Date
August 25, 1956
Authors
F. W. Wolff
G. A. Stewart
M. F. Crowley
A. Bloom
Publisher
BMJ
Related search
Effect of Oral Hypoglycaemic Agents on Glucose Tolerance in Pancreatic Diabetes
Gut
Gastroenterology
Oral Hypoglycaemic Agents
Toxicology Case of the Month: Oral Hypoglycaemic Overdose
Emergency Medicine Journal
Medicine
Critical Care
Emergency Medicine
Intensive Care Medicine
A 1-Year Safety Study of Dulaglutide in Japanese Patients With Type 2 Diabetes on a Single Oral Hypoglycemic Agent: An Open-Label, Nonrandomized, Phase 3 Trial
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Hypoglycaemic and Insulinotropic Effects of a Novel Oral Antidiabetic Agent, (Â)-N-(Trans-4-Isopropylcyclohexane-Carbonyl)-D-Phenylalanine (A-4166)
British Journal of Pharmacology
Pharmacology
Oral Bioavailability and Hypoglycaemic Activity of Tolbutamide/Cyclodextrin Inclusion Complexes
International Journal of Pharmaceutics
Pharmaceutical Science
HLA Phenotype and Secondary Failure to Oral Hypoglycaemic Agents
Diabetologia
Internal Medicine
Endocrinology
Metabolism
Diabetes
Association of Insulin Treatment Versus Oral Hypoglycaemic Agents With Diabetic Retinopathy and Its Severity in Type 2 Diabetes Patients in Cameroon, Sub-Saharan Africa
Annals of Translational Medicine
Medicine
Participant and Parent Experiences in the Oral Insulin Study of the Diabetes Prevention Trial for Type 1 Diabetes
Pediatric Diabetes
Internal Medicine
Pediatrics
Endocrinology
Perinatology
Child Health
Metabolism
Diabetes
